| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/SONC.2002.31523 |
| P698 | PubMed publication ID | 11894014 |
| P50 | author | Marileila Varella-Garcia | Q44517034 |
| Fred R Hirsch | Q89864676 | ||
| P2093 | author name string | Wilbur A Franklin | |
| Paul A Bunn | |||
| Robert Veve | |||
| P433 | issue | 1 Suppl 4 | |
| P304 | page(s) | 51-58 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | HER2/neu expression in malignant lung tumors | |
| P478 | volume | 29 |
| Q37667783 | Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients |
| Q38544205 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial |
| Q37390655 | Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas |
| Q56379383 | Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial |
| Q45210729 | Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). |
| Q39298725 | Current status of research and treatment for non-small cell lung cancer in never-smoking females |
| Q40420569 | Cytoplasmic expression of c-erbB2 in non-small cell lung cancers |
| Q42106918 | Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study |
| Q35179403 | EGF receptor as a therapeutic target |
| Q42485639 | EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study |
| Q33878879 | ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss |
| Q39821603 | ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas |
| Q35581167 | Emerging drugs for non-small cell lung cancer |
| Q38331804 | Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis |
| Q79401515 | Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus |
| Q39729571 | Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. |
| Q50877452 | Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients |
| Q90457751 | Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China |
| Q39183138 | Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab |
| Q35790212 | Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain |
| Q33704088 | New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib |
| Q42948972 | Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab |
| Q37579647 | Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer |
| Q34935948 | RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer |
| Q38104414 | Rare mutations in non-small-cell lung cancer |
| Q61450189 | Role of RNA-binding protein 5 in the diagnosis and chemotherapeutic response of lung cancer |
| Q26745776 | Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far |
| Q41612592 | Structural basis of a novel heterodimeric Fc for bispecific antibody production |
| Q38127728 | Targeted therapy for NSCLC with driver mutations |
| Q37278752 | The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. |
| Q35013566 | The role of new agents in the treatment of non-small cell lung cancer. |
| Q35590979 | Trastuzumab for the treatment of non-small-cell lung cancer |
| Q40027537 | Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. |
| Q74092388 | What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? |
| Q54658801 | [A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]. |
Search more.